Equal-WT
WhaleScore 2.0
?
SARISSA CAPITAL MANAGEMENT LP
0
followers
·
Follow
GREENWICH CT
Investment Advisor
Hedge Fund
Activist Investor
Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. Sarissa Capital Management is a hedge fund with 10 clients and discretionary assets under management (AUM) of $926,987,169 (Form ADV from 2024-03-29). Their last reported 13F filing for Q2 2024 included $592,420,772 in managed 13F securities
and a top 10 holdings concentration of 100.0%. Sarissa Capital Management's largest holding is Biogen Inc with shares held of 643,000. Whalewisdom has at least 44 13F filings, 84 13D filings, and 3 13G filings
Business Description
Sarissa provides advisory services to clients, managing their investments and allocating resources accordingly. The firm may utilize "Soft Dollar Items" such as research reports, economic surveys, and recommendations for specific securities to assist in investment decision-making.
Sarissa prioritizes dedicating sufficient time and resources to its advisory clients. However, the firm may engage in other business activities, including establishing investment funds or SMAs, which could potentially create conflicts of interest. These activities may involve allocating time and resources between advisory clients and other ventures, potentially impacting the level of dedication to individual clients.
Investment Strategy
Sarissa may offer any advisory services, engage in any investment strategy, and make any investment, including any not described in this Brochure, that Sarissa considers appropriate, subject to each Advisory Client’s investment objectives and guidelines. The investment strategies that Sarissa pursues are speculative and entail substantial risks.
The Funds expect to focus its investments in the healthcare and healthcare-related sub-sectors, and such companies or industries may have high positive correlations to one another, the Funds may be particularly vulnerable to events affecting such sectors and industries.
Owners
(Subscription Required)
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-06-30
Top Buys (13F)
| Name | % Change |
|---|---|
| CYTK Cytokinetics Inc | 6.47% |
| NBIX Neurocrine Bioscienc | 1.18% |
2024-06-30
Top Sells (13F)
| Name | % Change |
|---|
2024-06-30
13F Holdings Summary
| Name | $ Change |
|---|---|
| BIIB Biogen Inc | 25.16% |
| INVA Innoviva Inc | 20.14% |
| IRWD Ironwood Pharmaceuti | 18.04% |
| GILD Gilead Sciences Inc. | 12.78% |
| CYTK Cytokinetics Inc | 10.15% |
2024-06-30
13F Activity
| Market Value | $0.59b, Prior: $0.57b |
| Inflows (Outflows) as % of Total MV | +8.8965% |
| New Purchases | 0 stocks |
| Added To | 2 stocks |
| Sold out of | 0 stocks |
| Reduced holdings in | 0 stocks |
| Top 10 Holdings % | 100% |
| Turnover %[1] | 0% |
| Turnover Alt %[2] | 0% |
| Time Held Top 20 | 16.9 quarters |
| Time Held Top 10 | 15.1 quarters |
| Time Held All | 16.9 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-06-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-06-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-06-30